Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of August 2025, with the specific transaction date being August 19, 2025. The filing serves as a disclosure of share repurchases executed under a pre-existing non-discretionary agreement with Merrill Lynch International.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 211,358 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,430.50p; highest price paid was 1,452.50p.
- Average Price: Volume-weighted average price paid was 1,442.73p.
- Trading Venue: All purchases were executed on the London Stock Exchange (XLON).
- Treasury Share Holdings: Following this purchase, GSK holds 242,710,027 ordinary shares in treasury.
- Shares in Issue: 4,072,681,707 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.96% of the total voting rights.
Material Changes and Program Status
This transaction is part of GSK's existing buyback programme initiated via a non-discretionary agreement on June 4, 2025. Since the commencement of this agreement, the company has purchased an aggregate of 24,575,644 ordinary shares. The filing confirms the ongoing execution of this capital return strategy.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or specific management commentary regarding operational outlook is provided in this document.
Key Facts for Investor Verification
- Verify the total cumulative buyback volume since June 4, 2025 (24,575,644 shares).
- Confirm the current percentage of voting rights held in treasury (5.96%) against regulatory thresholds.
- Review the specific transaction prices (1,430.50p to 1,452.50p) to assess execution relative to market conditions on August 19, 2025.
- Check the remaining capacity under the non-discretionary agreement with Merrill Lynch International.